Cell therapies including so-called “stem cells” are increasingly being marketed and used for the treatment of musculoskeletal disorders – despite questions about these treatments and their effectiveness. A new tool for standardizing communication about cell therapies is presented in the May 15 issue of The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.
Called “DOSES,” the new tool provides standards for describing the characteristics and use of cell therapies. Developed by an international expert panel, “The use of this tool may allow clinicians and patients to better understand the characteristics of current and future cell preparations,” according to the new report’s senior author, Robert F. LaPrade, MD, PhD, of The Steadman Clinic, Vail, Colo.
Read Study Abstract: International Expert Consensus on a Cell Therapy Communication Tool: DOSES
Read Press Release: What Do They Mean by ‘Stem Cells’? Recommended Guidelines for Reporting on Cell Therapies
